Cell Pathways, Inc. Announces Earnings Conference Call Tuesday, July 30, 2002 at 8:30 a.m. ET.Business Editors and Health/Medical Writers BIOWIRE2K HORSHAM Horsham (hôr`shəm), town (1991 pop. 38,356) and district, West Sussex, SE England. Horsham is known primarily for its agricultural and merchandising activities, but it also serves as an engineering center. , Penn.--(BUSINESS WIRE)--July 19, 2002 Cell Pathways, Inc. (Nasdaq:CLPA CLPA CC-Link Partner Association CLPA Club Loisirs et Plein Air (Montpellier, France) CLPA Child Labour Programme of Action (national plan to eliminate child labour in South Africa) ) will release its second quarter financial results before the market opens on Tuesday Tuesday: see week. , July July: see month. 30, 2002. Cell Pathways will hold a teleconference and simultaneous webcast to discuss this information on July 30, 2002 beginning at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time). The webcast will be accessible through the company web site at www.cellpathways.com. A replay of the teleconference will be accessible following the end of the call. Both the webcast and replay will be available for 48 hours.
The dial-in information is as follows:
Within the U.S. please dial: 888/532-5130
Outside of the U.S. please dial: 904/779-4755
Reference call identification number: 13062334
The replay information is as follows:
Within the U.S. please dial: 800/252-6030
Outside of the U.S. please dial: 402/220-2491
Reference call identification number: 13062334
About Cell Pathways Cell Pathways, Inc., headquartered in Horsham, Penn., is a development stage pharmaceutical company focused on the research and development of novel and unique medications to treat and prevent cancer and to treat certain inflammatory diseases Noun 1. inflammatory disease - a disease characterized by inflammation disease - an impairment of health or a condition of abnormal functioning NEC, necrotizing enterocolitis - an acute inflammatory disease occurring in the intestines of premature infants; . The company additionally markets and sells oncology-related products manufactured by others. The company's initial drug candidates in clinical development are Aptosyn(R) (exisulind Exisulind is a drug used to treat cancer. It acts by inhibiting the enzyme cyclic guanosine monophosphate phosphodiesterase. Tademark by OSI Pharmaceuticals is Aptosyn. ) and CP461. For additional information on Cell Pathways, Inc., visit the Company's web site at http://www.cellpathways.com. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion